Incyte is set to acquire Vega Therapeutics in a deal worth up to $2 billion. The acquisition is expected to expand Incyte's hematology pipeline, with Vega reportedly having a phase III candidate for a bleeding disorder. The move may be part of Incyte's strategy to grow its portfolio, although some reports mention a different target, Star, which may be related to Vega or a separate entity.